Endovascular Today
Simcere’s Sanbexin Before Thrombectomy Studied to Improve Outcomes After AIS in TASTE-2. November 19, 2024—Simcere Pharmaceuticals Group Ltd. recently announced that findings …
News - Endovascular Today
November 14, 2024. Arsenal Medical’s EMBO-02 Study of NeoCast Liquid Embolic for cSDH Begins in Australia. November 14, 2024—Arsenal Medical announced the initiation of the …
Venous - Endovascular Today
Study Assesses Effects of Intravascular Volume Expansion on Deep Pelvic Vein Size. November 3, 2024—A study assessed the effects of intravascular volume expansion on deep pelvic vein …
May 2024 Issue - Endovascular Today
Spur RST: Maximizing BTK CLTI Treatment Outcomes Without Compromising Safety. Physicians describe their experiences using the Spur Retrievable Scaffold followed by a DCB as a novel …
Xeltis Receives FDA Breakthrough Device Designation for aXess …
2 days ago · November 19, 2024—Xeltis recently announced that the FDA has granted Breakthrough Device designation for the company’s aXess vascular access conduit and that …
January 2024 Issue - Endovascular Today
Exploring the Pulmonary Embolism Interventional Trial Landscape. The current PE clinical study landscape, how PE trials compare with DVT trials, lessons learned from single-center studies, …
1-Year Data Presented From enVVeno’s VenoValve Pivotal Trial
2 days ago · November 20, 2024—enVVeno Medical Corporation announced 1-year data on all patients from SAVVE, the United States pivotal trial of the company’s VenoValve, a surgical …
About - Endovascular Today
About Endovascular Today. Endovascular Today (ISSN 1551-1944 print and ISSN 2689-792X online) is a publication dedicated to bringing you comprehensive coverage of all the latest …
Venous - Endovascular Today
Nov 3, 2024 · Study Assesses Effects of Intravascular Volume Expansion on Deep Pelvic Vein Size. November 3, 2024—A study assessed the effects of intravascular volume expansion on …
Humacyte’s ATEV Results Presented From V007 Phase 3 AV Access …
November 13, 2024—Humacyte, Inc. recently announced the presentation of results from the V007 phase 3 clinical trial of the company’s acellular tissue engineered vessel (ATEV) in …